CymaBay Therapeutics announced that it has commenced an underwritten public offering of an aggregate of $150M of its common stock and pre-funded warrants. All shares of common stock and pre-funded warrants to be sold in the offering will be offered by CymaBay. CymaBay anticipates using the net proceeds from the offering to fund ongoing development of seladelpar, including clinical trials targeting market expansion, and for working capital and general corporate purposes. Piper Sandler, Raymond James, Cantor and LifeSci Capital are acting as the joint book-running managers for the offering. BTIG is acting as the lead manager for the offering.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on CBAY:
- CymaBay Announces Pricing of Upsized $225 Million Public Offering of Common Stock and Pre-Funded Warrants
- CymaBay Announces Proposed $150 Million Public Offering of Common Stock and Pre-Funded Warrants
- CymaBay price target raised to $24 from $22 at BTIG
- CymaBay price target raised to $22 from $16 at B. Riley
- CymaBay (NASDAQ:CBAY) Rises on Promising Phase 3 Results in Liver Disease